JAK-STAT signaling pathway and its inhibitors in the treatment of atopic dermatitis
- VernacularTitle:JAK-STAT信号通路及其抑制剂在特应性皮炎治疗中的应用
- Author:
Zengyunou ZHANG
1
;
Xinying CAI
;
Fengli XIAO
Author Information
- From: Chinese Journal of Dermatology 2020;53(8):661-664
- CountryChina
- Language:Chinese
- Abstract: Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling pathway plays an important role in immune pathways in atopic dermatitis (AD) . Drugs that block the JAK-STAT signaling pathway, such as classic JAK inhibitors tofacitinib, ruxolitinib, etc., have been gradually applied to the treatment of AD in clinical trials, and good clinical efficacy has been achieved. In addition, other inhibitors of the JAK-STAT signaling pathway, such as apamin and dupilumab, also show some efficacy in the treatment of AD. This review summarizes recent studies on the JAK-STAT signaling pathway and its inhibitors.
